Revvity to acquire ACD/Labs in research informatics expansion
Revvity has entered into a definitive agreement to acquire ACD/Labs, a global provider of scientific software solutions supporting analytical characterisation and molecular design across pharmaceutical and material sciences sectors.
The acquisition will integrate ACD/Labs’ expertise in analytical and process chemistry into Revvity Signals’ existing platform, creating a unified software as a service environment spanning molecular design, analytical science, and manufacturing quality control. This expansion aims to bridge the gap between analytical data and actionable insights throughout the scientific workflow, from discovery and development through to scale-up and manufacturing.
Complementary software platforms to merge
ACD/Labs brings several established software tools to the integration. The Spectrus Platform provides advanced spectral analysis capabilities, whilst the Percepta Platform offers AI-driven molecular property and ADMET prediction. Additional specialised applications include Katalyst D2D for parallel and high-throughput experimentation, Luminata for pharmaceutical chemistry, manufacturing and controls decision support, and ADMS for enterprise analytical data management.
Kevin Willoe, president of Revvity Signals Software, said: “By integrating ACD/Labs’ technologies into the Revvity Signals platform, we’re giving our customers across pharmaceuticals and material sciences a truly unified SaaS environment – one that connects molecular design, analytical science, and manufacturing quality control within a single, end-to-end solution.”
Three decades of analytical software expertise
ACD/Labs has operated as a scientific software provider for more than 30 years, with its tools helping scientists identify and characterise molecules, monitor purity and quality, and deliver robust production processes. The company’s science-centric solutions offer harmonised, AI-ready analytical, structural, and molecular information with FAIR-compliance, whilst its cloud-enabled technologies enable chemically intelligent knowledge proliferation and workflow automation.
Daria Thorp, president and CEO of ACD/Labs, said: “For more than three decades, our scientists, informaticians, and software developers have been recognised as leaders in analytical and chemical intelligence. Joining the Revvity Signals team brings together two industry leaders with a shared commitment to innovation in scientific software.
Together, we will expand the reach of our technology and deliver unified, end-to-end solutions that empower customers with deeper insight and greater scientific continuity.”
